This is a working overview of dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilized peptide powder form |
| Solubility | Soluble in aqueous buffer | Dissolves in water and buffered saline |
| Typical storage temperature | 2 to 8 degrees Celsius | Refrigerated; protect from freezing and light |
| Common analytical method | Reversed-phase HPLC | Purity and related substances |
| Mass confirmation | Electrospray mass spectrometry | Verifies approximately 4,813 Da |
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Even though slavery is now outlawed in every country, the number of slaves today is estimated as between 12 million and 29.8 million. According to a broad definition of slavery, there were 27 million people in slavery in 1999, spread all over the world. In 2005, the International Labour Organization provided an estimate of 12.3 million forced labourers. Siddharth Kara has also provided an estimate of 28.4 million slaves at the end of 2006 divided into three categories: bonded labour/debt bondage (18.1 million), forced labour (7.6 million), and trafficked slaves (2.7 million). Kara provides a dynamic model to calculate the number of slaves in the world each year, with an estimated 29.2 million at the end of 2009.
== Participation in the creation-evolution debate == Wickramasinghe and his mentor Fred Hoyle have also used their data to argue in favor of cosmic ancestry, and against the idea of life emerging from inanimate objects by abiogenesis.
The so-called carbamate insecticides feature the carbamate ester functional group (ROC(O)NHR'). Included in this group are aldicarb (Temik), carbofuran (Furadan), carbaryl (Sevin), ethienocarb, fenobucarb, oxamyl, and methomyl. They are synthetic analogues of the toxic alkaloid physostigmine, the study of which led to this class of insecticides. An estimated 25M kg of carbaryl were produced in 1971. These insecticides kill insects by reversibly inactivating the enzyme acetylcholinesterase (AChE inhibition) (IRAC mode of action 1a). Fenoxycarb has a carbamate group but acts as a juvenile hormone mimic, rather than inactivating acetylcholinesterase. The insect repellent icaridin is a substituted carbamate. Besides their common use as arthropodocides/insecticides, they are also nematicidal. One such is Oxamyl. Sales have declined dramatically over recent decades.
Gus Sackey (David Jonsson) is a new grad at Pierpoint, and one of the series' protagonists during the first two series. He is initially assigned to the Investment Banking Division (IBD) and transferred to the CPS desk after the death of his colleague Hari Dhar. Gus is openly gay and hails from an elite background, having graduated literae humaniores from both Eton College and the University of Oxford. Despite his upper-class upbringing, Gus is shown to be humble and morally principled, and feels undervalued within Pierpoint's cutthroat work culture. In series 1, Gus struggles to find a clear role after his team is dissolved and repeatedly alienates senior staff through his bluntness and frustration, including London office head Sara Dhadwal and his manager Clement Cowan. He also rekindles an affair with his former classmate Theo Tuck. On RIF day, Gus delivers a deliberately unserious presentation—beginning by reading from a note written as part of a bet—before walking out, and is not offered a permanent position. In series 2, Gus re-emerges working in politics after striking up a connection with MP Aurore Adekunle, who hires him as an aide. Gus feels fulfilled by the work—which largely involves speaking with everyday constituents about their struggles—despite his sister Sadie's objections. While working for Aurore, Gus begins a relationship with Leo Bloom, the son of hedge fund manager Jesse Bloom, and later leaks confidential government information about the approval of Amazon’s acquisition of pharmaceutical company FastAide to Harper.
=== Use in supplements aimed at eye health === In 2013, the Age-Related Eye Disease Study 2 (AREDS2) reported a reduced risk of visual loss and a reduced risk of disease progression over 5 years in 4,200 participants with early or moderate age-related macular degeneration (AMD) who were supplemented with a formulation containing the macular carotenoids and co-antioxidants. The AREDS2 preparation contained only two of the macular pigment’s three carotenoids (lutein and 3R,3´R-zeaxanthin), and did not include meso-zeaxanthin, which is the dominant carotenoid at the centre of the macula, the presence of which is essential for maximum collective antioxidant effect. Studies have shown that the addition of meso-zeaxanthin to formulations used to increase MP and enhance visual function in diseased and healthy retinas has proven effective. Trials have shown that a formulation containing all three macular carotenoids in a meso-zeaxanthin:lutein:zeaxanthin (mg) ratio of 10:10:2 is superior to alternative formulations, in terms of visual improvements and in observed increases in MP.
Sources: en.wikipedia.org
DNA sequencing research, using microfluidics, also has the ability to be applied to the sequencing of RNA, using similar droplet microfluidic techniques, such as the method, inDrops. This shows that many of these DNA sequencing techniques will be able to be applied further and be used to understand more about genomes and transcriptomes.
WDIND*.*P..*...D.F.*W***.**.IYS**...A.*H*S*WAMRNTNNHN Here each . signifies a single amino acid or a gap, and each * indicates one member of a closely related family of amino acids. The authors were able to show that the motif has DNA binding activity. A similar approach is commonly used by modern protein domain databases such as Pfam: human curators would select a pool of sequences known to be related and use computer programs to align them and produce the motif profile (Pfam uses HMMs, which can be used to identify other related proteins. A phylogenetic approach can also be used to enhance the de novo MEME algorithm, with PhyloGibbs being an example.
BOAC threatened to cancel its order, and Heseltine several times summoned the board, who had threatened to resign en masse, to his office, impressing Parkinson by his skills of persuasion. Civil servants were happy that his love of generating headlines helped the cause of Concorde sales. The queen, Princess Margaret and Princess Anne were all seen accompanying Heseltine on board Concorde to drum up publicity. In the summer of 1972 he sent Concorde 002 on a tour of Iran, India, Singapore, Japan and Australia. Heseltine and his wife Anne accompanied the plane as far as Singapore (the press joked that Lee Kuan Yew might not let him in with such long hair), and he met it at Toulouse on the way back, but not a single plane was sold. By this stage there were options to sell 74 Concordes to 17 airlines around the world (the original hope had been to sell 30), but this went wrong because of the rises in the oil price in 1973 and 1979; in the event only 10 were ever sold, five each to British Airways (as BOAC had become in 1974) and Air France. Heseltine won praise for his efforts at salesmanship, but some civil servants felt that he was more committed to the plane than Tony Benn had been, and that he should have acted decisively to cut back marketing efforts sooner than he did. He did not mention Concorde at all in his books Where There's A Will or The Challenge of Europe. Heseltine was a key mover in the setting up of the European Space Agency (ESA) in 1973. He cancelled the British Geostationary Technological satellite and handed back the grant to the Treasury.
== Reducing agent == DTT is a reducing agent; once oxidized, it forms a stable six-membered ring with an internal disulfide bond. It has a redox potential of −0.33 V at pH 7. The reduction of a typical disulfide bond proceeds by two sequential thiol-disulfide exchange reactions and is illustrated below. The reduction usually does not stop at the mixed-disulfide species because the second thiol of DTT has a high propensity to close the ring, forming oxidized DTT and leaving behind a reduced disulfide bond. The reducing power of DTT is limited to pH values above 7, since only the negatively charged thiolate form -S− is reactive (the protonated thiol form -SH is not); the pKa of the thiol groups is 9.2 and 10.1.
Sources: en.wikipedia.org
The Financial Times reported that "the test showed that China had made astounding progress on hypersonic weapons and was far more advanced than U.S. officials realized." During the Zapad 2021 joint strategic exercise, most of the gear comprised novel Chinese arms such as the KJ-500 airborne early warning and control aircraft, J-20 and J-16 fighters, Y-20 transport planes, and surveillance and combat drones. Another joint forces exercise took place in August 2023 near Alaska. On 24 September 2024, the PLARF performed its first intercontinental ballistic missile (ICBM) test over the Pacific Ocean since the early 1980s.
Researchers have not found enough variability within the genus to confidently delineate similar species, due to a low rate in mutation of mitochondrial DNA. Environmental factors, such as the rise of temperatures and acid levels in our oceans account for some speciation of corals in the form of species lost. Various coral species have heat shock proteins (HSP) that are also in the category of DE across species. These HSPs help corals combat the increased temperatures they are facing which lead to protein denaturing, growth loss, and eventually coral death. Approximately 33% of coral species are on the International Union for Conservation of Nature's endangered species list and at risk of species loss. Ocean acidification (falling pH levels in the oceans) is threatening the continued species growth and differentiation of corals. Mutation rates of Vibrio shilonii, the reef pathogen responsible for coral bleaching, heavily outweigh the typical reproduction rates of coral colonies when pH levels fall. Thus, corals are unable to mutate their HSPs and other climate change preventative genes to combat the increase in temperature and decrease in pH at a competitive rate to these pathogens responsible for coral bleaching, resulting in species loss.
== External links == Clinical trial number NCT04020341 for "A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)" at ClinicalTrials.gov Clinical trial number NCT04187144 for "Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)" at ClinicalTrials.gov
Sources: en.wikipedia.org
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.
Mass spectrometry establishes the molecular mass and can detect sequence variants. Reversed-phase chromatography assesses purity and related substances. Peptide mapping after digestion confirms the amino acid sequence itself.
Typical fields include appearance, purity by chromatographic area, mass confirmation, and water or counterion content. Some documents also list residual solvents and microbial limits. The specific fields depend on the supplier and the intended application.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.